Zafgen’s (ZFGN) “Hold” Rating Reiterated at FBR & Co
Zafgen Inc. (NASDAQ:ZFGN)‘s stock had its “hold” rating restated by research analysts at FBR & Co in a report issued on Tuesday.
A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research note on Tuesday, July 26th. Cowen and Company reaffirmed a “buy” rating and set a $60.00 price target on shares of Zafgen in a research note on Thursday, August 25th. Canaccord Genuity set a $4.00 price target on Zafgen and gave the stock a “hold” rating in a research note on Thursday, July 21st. Finally, Leerink Swann reaffirmed a “market perform” rating and set a $6.00 price target on shares of Zafgen in a research note on Wednesday, July 20th. Six analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $14.22.
Zafgen (NASDAQ:ZFGN) traded down 2.40% during midday trading on Tuesday, hitting $3.26. The company had a trading volume of 1,408,272 shares. The company’s 50 day moving average is $3.13 and its 200-day moving average is $5.42. Zafgen has a one year low of $2.90 and a one year high of $44.98. The company’s market cap is $89.09 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/zafgens-zfgn-hold-rating-reiterated-at-fbr-co.html
In other Zafgen news, CFO Patricia L. Allen bought 16,000 shares of the stock in a transaction on Tuesday, July 26th. The shares were purchased at an average price of $3.12 per share, with a total value of $49,920.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Thomas E. Hughes bought 10,000 shares of the stock in a transaction on Monday, August 29th. The stock was acquired at an average cost of $3.00 per share, for a total transaction of $30,000.00. Following the acquisition, the insider now directly owns 63,936 shares in the company, valued at $191,808. The disclosure for this purchase can be found here. 20.30% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Institutional Trust Company N.A. raised its stake in Zafgen by 23.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 503,109 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 95,945 shares during the period. BlackRock Fund Advisors raised its stake in Zafgen by 18.3% in the second quarter. BlackRock Fund Advisors now owns 929,566 shares of the biopharmaceutical company’s stock worth $5,568,000 after buying an additional 143,670 shares during the period. BlackRock Investment Management LLC raised its stake in Zafgen by 51.9% in the second quarter. BlackRock Investment Management LLC now owns 89,327 shares of the biopharmaceutical company’s stock worth $535,000 after buying an additional 30,515 shares during the period. Vanguard Group Inc. raised its stake in Zafgen by 18.2% in the second quarter. Vanguard Group Inc. now owns 805,362 shares of the biopharmaceutical company’s stock worth $4,824,000 after buying an additional 123,850 shares during the period. Finally, California State Teachers Retirement System raised its stake in Zafgen by 33.8% in the second quarter. California State Teachers Retirement System now owns 47,925 shares of the biopharmaceutical company’s stock worth $287,000 after buying an additional 12,104 shares during the period. 62.83% of the stock is currently owned by hedge funds and other institutional investors.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.